BaFin Expands Audit of Gerresheimer AG's Financial Reports

The German Federal Financial Supervisory Authority (BaFin) has announced an expansion of its audit of Gerresheimer AG's 2024 consolidated financial statements. The audit, initially started in September 2025, focuses on concerns about lease liabilities and asset impairments, particularly in Advanced Technologies and Sensile Medical AG.

Additionally, BaFin is initiating an audit of the 2025 Half-Year Financial Report due to potential inaccuracies in risk assessment related to Bormioli Pharma's acquisition and issues with bill and hold agreements' revenue recognition. Gerresheimer had already decided to correct these revenue figures in 2026.

Gerresheimer AG expects the expanded audits and intends to fully cooperate with BaFin to ensure transparent clarification of the facts. These audits will evaluate financial reporting accuracy and could impact future financial disclosures.